Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105518 | 1.00 | PTPN11 (0.38) | PTPN11ADRB2ADRB1ADRB3TAS1R3 | |
| SCHEMBL3014363 | 0.91 | GAA (0.44) | PTPN11GAARAB9ASYKKLK5 | |
| SCHEMBL175887 | 0.91 | PTPN11 (0.41) | PTPN11L3MBTL1 | |
| SCHEMBL12064331 | 0.91 | PTPN11 (0.41) | PTPN11L3MBTL1 | |
| SCHEMBL3014367 | 0.91 | GAA (0.44) | PTPN11GAARAB9ASYKKLK5 | |
| SCHEMBL3013330 | 0.86 | GAA (0.46) | PTPN11GAARAB9ASYK | |
| SCHEMBL12380408 | 0.86 | MEN1 (0.49) | PTPN11ADRB2ADRB1ADRB3RAB9A | |
| SCHEMBL175765 | 0.85 | TAS1R3 (0.39) | ADRB2ADRB1ADRB3TAS1R3TAS1R1 | |
| SCHEMBL18023346 | 0.84 | GAA (0.41) | PTPN11GAARAB9ASYKKLK5 | |
| SCHEMBL9925881 | 0.84 | TAS1R3 (0.41) | PTPN11TAS1R3TAS1R1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1618087-A4 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1618087-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | PTPN11 3357/4885ADRB2 2728/4885ADRB1 1968/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | PTPN11 3667/4885ADRB2 4195/4885ADRB1 3853/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | PTPN11 3357/4885ADRB2 2728/4885ADRB1 1968/4885 |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | PTPN11 3418/4885ADRB2 2699/4885ADRB1 2114/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | PTPN11 3357/4885ADRB2 2728/4885ADRB1 1968/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | PTPN11 3357/4885ADRB2 2728/4885ADRB1 1968/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | PTPN11 3357/4885ADRB2 2728/4885ADRB1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.